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Differential expression of CD148 on leukocyte
subsets in inflammatory arthritis
Richa K Dave1,2, Amy J Naylor3, Stephen P Young3, Rachel Bayley3, Debbie L Hardie3, Oliver Haworth3,
David A Rider3, Andrew D Cook4, Christopher D Buckley3 and Stuart Kellie1,2,3,5*
Abstract
Introduction: Monocytic cells play a central role in the aetiology of rheumatoid arthritis, and manipulation of the
activation of these cells is an approach currently under investigation to discover new therapies for this and
associated diseases. CD148 is a transmembrane tyrosine phosphatase that is highly expressed in monocytes and
macrophages and, since this family of molecules plays an important role in the regulation of cell activity, CD148 is
a potential target for the manipulation of macrophage activation. For any molecule to be considered a therapeutic
target, it is important for it to be increased in activity or expression during disease.
Methods: We have investigated the expression of CD148 in two murine models of arthritis and in joints from
rheumatoid arthritis (RA) patients using real-time PCR, immunohistochemistry, and studied the effects of
proinflammatory stimuli on CD148 activity using biochemical assays.
Results: We report that CD148 mRNA is upregulated in diseased joints of mice with collagen-induced arthritis.
Furthermore, we report that in mice CD148 protein is highly expressed in infiltrating monocytes of diseased joints,
with a small fraction of T cells also expressing CD148. In human arthritic joints both T cells and monocytes
expressed high levels of CD148, however, we show differential expression of CD148 in T cells and monocytes from
normal human peripheral blood compared to peripheral blood from RA and both normal and RA synovial fluid.
Finally, we show that synovial fluid from rheumatoid arthritis patients suppresses CD148 phosphatase activity.
Conclusions: CD148 is upregulated in macrophages and T cells in human RA samples, and its activity is enhanced
by treatment with tumour necrosis factor alpha (TNFa), and reduced by synovial fluid or oxidising conditions. A
greater understanding of the role of CD148 in chronic inflammation may lead to alternative therapeutic
approaches to these diseases.
Introduction
Mononuclear phagocytes ingest and destroy foreign
microorganisms and act as antigen-presenting cells,
thereby regulating both innate and acquired immunity
by the release of proinflammatory products in response
to pathogen-associated molecular patterns (PAMPs)
[1-3]. Such responses commonly involve protein phos-
phorylation mediated by the selective activation of pro-
tein tyrosine kinases (PTKs), with further modulation by
tyrosine phosphatases (PTPs). However, perturbation of
the balance between PTK and PTP activity may result in
a failure of inflammation to resolve leading to life-threa-
tening chronic inflammatory diseases [4-8].
CD148 (PTPRJ; DEP-1; PTPh; Byp or PTPb-like tyro-
sine phosphatase) is a receptor PTP containing a single
cytoplasmic phosphatase domain and an extracellular
domain containing eight to twelve fibronectin type III
(FNIII) repeats [9]. Detectable in a wide range of cells
[10,11], its reduced expression in some malignant
tumours, coupled with the reversion of the transformed
phenotype when CD148 function is restored, implies a
role as a tumour suppressor [12-14]. Identified sub-
strates/binding partners include Src family tyrosine
kinases (SFK) [15,16], platelet-derived growth factor
(PDGF) b-receptor [17], hepatocyte growth factor (HGF)
receptor[18], vascular endothelial growth factor (VEGF)
receptor-2 [19,20] and the p85 subunit of PI3-kinase
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[21]. In haemopoietic cells, it appears that CD148 has a
positive role in enhancing SFK signalling by dephosphory-
lating a negative regulatory phosphotyrosine [15,16,22]. In
contrast, dephosphorylation of PDGF-b receptor HGF
receptor and VEGF receptor-2 appear to result in attenua-
tion of proliferative responses to PDGF, HGF and VEGF
respectively. By inhibiting phosphorylation of p85, CD148
can inhibit PI3 kinase activation, thereby potentially inhi-
biting any PI3 kinase-dependent proliferative signals [21].
In addition, p120 catenin [23], occludin and ZO-1 [24]
have been identified as substrates or binding partners in
epithelial cells. CD148-mediated dephosphorylation of
these proteins leads to modulation of cell-cell adhesions
[24,25].
CD148 expression is upregulated by cell density in some
epithelial cells [26], and it plays a role in fibroblast [27]
and monocyte [28] migration. However, although macro-
phages have the highest expression levels of CD148
[29,30], relatively little is known about its regulation and
function in these cells. CD148 expression is upregulated
by lipopolysaccharide (LPS) and downregulated by colony-
stimulating factor 1 (CSF-1) [31]. In T cells, CD148 is
excluded from the immunologic synapse and is able to
reduce T cell receptor signalling [15,32,33]. CD148 depho-
sphorylates the negative regulatory tyrosine in SFKs in a
manner similar to CD45 [15,16] and is essential for Legio-
nella pneumophila phagocytosis and effector translocation
[34]. More recently, a distinct function for CD148 in neu-
trophil chemotaxis has been reported [35]. Here we show
that CD148 expression is upregulated in murine models of
rheumatoid arthritis and in human rheumatoid arthritis,
and show that this is primarily a result of expression by
monocytic cells in mice and in both monocytic cells and T
cells in humans within the joint lesions. An understanding
of the biology of phosphatases such as CD148 in macro-
phage-specific signalling cascades may enable the identifi-
cation of key endogenous regulators of inflammation and
therapeutic targets for inflammatory diseases.
Materials and methods
Patients, peripheral blood and synovial tissue and
synovial fluid preparation
Samples from peripheral venous blood (PB) and synovial
fluid (SF) were collected into preservative-free heparin.
Peripheral blood lymphocytes (PBLs) were isolated as pre-
viously described [36]. Synovial tissue was taken at the
time of joint replacement and snap frozen in liquid nitro-
gen. All 39 patients with rheumatoid arthritis used in this
study fulfilled 1987 ACR classification criteria for rheuma-
toid arthritis (RA) [37]. Peripheral blood lymphocytes
(PBL) and synovial fluid lymphocytes (SFL) were isolated
as previously described [36]. SF was immediately centri-
fuged to remove cells and debris before storage in aliquots
at -70°C. All ethical approval and patient consent where
appropriate for the use of tissue samples taken at the time
of this study was obtained from the Birmingham Research
Ethics Committee (REC 2002/088 and LREC 5735).
Quantitative real-time PCR
RNA extraction from joint tissues was performed using
the RNeasy Mini Kit (Qiagen, Valencia, CA, USA) as per
the manufacturer’s instructions. RNA purity was ensured
by an A260/A280 of at least 1.8. Genomic DNA contamina-
tion was removed using DNase (Ambion, Austin, TX,
USA) and cDNA was generated using Superscript III
(Invitrogen, Carlsbad, CA, USA), using oligo-dT primers
(Geneworks, Adelaide, Australia). Specific cDNA was
quantitated in triplicate using SYBR Green (Applied
Biosystems, Foster City, CA, USA) in 20 μL reactions in a
96-well plate. Data was analysed using the ABI Prism
software. Gene expression was determined relative to hprt
(hypoxanthine-guanine phosphoribosyl transferase)
mRNA using the comparative threshold method. Unless
otherwise stated, error bars indicate the standard deviation
of duplicate cDNA quantitations each from three indepen-
dent preparations of cells and RNA extracts using
triplicate quantitations in the same thermal run. Where
indicated, significance values between samples were
analysed by a paired t test. Primers (f, forward; r, reverse)
used were as follows:
mouse csf1r f: CCAGAGCCCCCACAGATAA, r:
AGCTTGCTGTCTCCACGTTTG;
human csf 1 f: CCTTCAGGAGCAGGCCCAAG , r:
CCTTGCTCGCAGCAGGTCAG;
mouse CD148 f CAGTACAGTGAATGGGAGCACT-
GAC, r: GTCCGTATTCTGCCACTCCAACT;
human CD148 f: AGTACACACGGCCCAGCAAT, r:
GAGGCGTCATCAAAGTTCTGC;
mouse hprt f: GCAGTACAGCCCCAAAATGG, r:
AACAAAGTCTGGCCTGTATCCAA;
human hprt f: TCAGGCAGTATAATCCAAA-
GATGGT, r: AGTCTGGCTTATATCCAACACTTCG.
Antibodies
Monoclonal hamster anti-mouse CD148 antibody was
generated as described [11] and was a gift from Prof.
Arthur Weiss (Howard Hughes Medical Institute, Univer-
sity of California, San Francisco). Monoclonal anti-human
CD148 was neat supernatant from the IgG2a clone
8B11H3 [28]. Anti-CD3 (IgG2b clone UCHT-1 17 μg/ml
was a gift from Prof. Peter Beverley. Antibodies were
purchased from commercial sources: F4/80 and Mac-2
(Serotec, Kidlington, UK); CD68 (Becton Dickinson,
Franklin Lakes, NJ, USA); CD90 (Dianova, Hamburg, Ger-
many); von Willebrand Factor (vWF) (Dako, Glostrup,
Denmark). CD11c (IgG1 clone BU15 1 in 100 ascitis fluid)
was a locally sourced Birmingham University hybridoma.
Secondary antibodies were goat anti-mouse IgG1-FITC,
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IgG2a-TRITC and IgG2b-Cy5 (Southern Biotech,
Birmingham, AL, USA); biotin-conjugated goat anti-rat
IgG (Serotec); biotin conjugated goat anti-hamster IgG
(Pierce, Rockford, IL, USA) and donkey anti-rabbit anti-
methyl coumarin (Jackson ImmunoResearch, West Grove,
PA, USA).
Murine collagen-induced arthritis model
Eight- to twelve-week-old DBA mice were injected intra-
dermally with chick collagen II in Freund’s complete adju-
vant and boosted 21 days later. This model has been
extensively described [38-40]. Groups of nine mice were
immunised with collagen and scored for arthritis onset
using a scale of 0 (normal) to 3 (joint distortion and/or
rigidity) for each limb two to three times per week for up
to 60 days [39]. Typically about 35% of limbs were unaf-
fected and 65% affected. Of the affected limbs, 50% display
a score of 3, as described previously [38-42]. Rear joints
were excised, fixed in 4% paraformaldehyde for 48 hours
and decalcified in 10% EDTA prior to processing for
paraffin embedding. Five micron serial sections were cut
for immunohistochemistry. Three limbs of score 3 and
controls were taken at day 35 post immunisation and
RNA was isolated and processed for qPCR.
KRN murine model for arthritis
Arthritis was induced in male, six-week-old C57Bl/6
mice (Harlan, Indianapolis, IN, USA) by intraperitoneal
injection of 100 μl serum from K/BxN mice (a generous
gift from Mohini Gray) as described [43,44]. Mice devel-
oped polyarthritis within 48 hours of the injection and
were sacrificed by cervical dislocation at the peak of
inflammation, three days after disease onset. Disease
was scored as described above. Limbs were dissected
and processed as described above.
Immunohistochemistry
Immunohistochemistry was performed as described pre-
viously [45]. Expression of CD148 and Mac-2 were exam-
ined in serial sections. Briefly, sections were deparaffinized
and rehydrated. For CD148, microwave antigen retrieval
was performed in citrate buffer pH 6.0 for 2 min and
allowed to cool overnight. For Mac-2 no antigen retrieval
was necessary. Sections were washed in Tris-buffered sal-
ine (TBS) blocked in 3% H2O2 then serum block (10%
fetal calf serum (FCS) plus 10% normal serum (species of
secondary antibody) in TBS) followed by primary antibody
for 60 min. Sections were subsequently incubated for 30
min with a biotinylated F(ab’)2 fragment of goat anti-rat
or rabbit anti-hamster immunoglobulin (DakoCytomation,
Glostrup, Denmark), followed by horseradish peroxidase
(HRP)-conjugated streptavidin (DakoCytomation), devel-
oped with DAB chromogen (DakoCytomation), and coun-
terstained with Mayer’s haematoxylin. The specificity of
the staining was confirmed by using matched isotype con-
trol antibodies. Sections were dried and mounted with
Cytoseal (Stephens Scientific, Riverdale, NJ, USA). Slides
were using an Olympus BX51 microscope with DP70
camera (Olympus, Tokyo, Japan).
Immunofluorescence
Five micron sections of snap-frozen tissue were air-dried
and fixed for 10 min in acetone at 4°C. Sections were
blocked for 1 hour at room temperature with 10% w/v
bovine serum albumin (BSA) and then stained overnight
at 4°C with primary antibodies. Sections were washed in
phosphate-buffered saline (PBS) and then incubated with
secondary antibodies for 1 hour at room temperature.
Nuclei in murine tissue were stained with 20 μg/ml
Hoechst 33258 (Bis-benzimid H33258 Fluorochrom, Rie-
del De Haen AG, Buchs, Switzerland). Sections were
mounted in 2.4% 1,4-Diazabicyclo(2.2.2)octane (Sigma-
Aldrich, St Louis, MO, USA) in glycerol (Fisons Scienti-
fic, Loughborough, UK) pH8.6. With reference to con-
trols, images were captured using a Zeiss LSM 510
confocal microscope (Carl Zeiss, Oberkochen, Germany).
Flow cytometry
Analysis of cell surface molecules was performed using
three-colour immunofluorescence as previously described
[36]. PBL and SFL were stained with the antibody cock-
tail of CD4 PE-Cy5 (1/50), CD8 FITC (1/20) and
CD45RO PE (1/50). The cells were positively gated on
the CD45 RO+ and then on CD4 PE-Cy5+ or CD8 FITC
+. The samples were analysed on an EPICS XL Flow cyt-
ometer (Beckman-Coulter Inc., Brea, CA, USA). Data was
analysed using WinMDI v2.8 (Scripps Institute, La Jolla,
CA, USA). Where indicated, significance values between
samples were analysed by a paired t test.
CD148 phosphatase assay
CD4 peripheral blood human T cells were activated using
anti-CD3 and gamma-irradiated Epstein-Barr virus (EBV)
B cells. On day 2 cells were harvested, washed and then
exposed to fresh medium containing SF from RA patients
diluted to 1:5 or 1:10. To measure CD148 phosphatase
enzyme activity a similar protocol to one we developed
for the related CD45 was used [46] Cells were washed
and lysed and CD148 captured onto protein A/CD148
Ab-coated 96-well plate and PTP activity assayed after
the addition of fluorescein diphosphate substrate. The
reaction was followed for an hour. Each assay was per-
formed in triplicate and corrected for background (no
capture antibody in the wells). Experiments were done
with eight different SFs and in triplicate. For hydrogen
peroxide treatment, two days after activation CD4 periph-
eral blood human T cells were exposed to hydrogen per-
oxide for 60 mins, lysed and CD148 phosphatase assay
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performed as described. For tumour necrosis factor alpha
(TNFa) treatment, 0.1 ng/ml fresh TNFa was added
daily for six days after which cells were lysed and CD148
phosphatase assay was performed. Where indicated, sig-
nificance values between samples were analysed by paired
t test.
Results
CD148 is upregulated in murine collagen-induced arthritis
Regulated expression of CD148 in macrophages in
response to inflammatory stimuli in vitro strongly sug-
gests a role in inflammation [31]. To investigate the
relevance of these findings in an in vivo disease model,
the expression of CD148 mRNA (ptprj) in collagen-
induced arthritis (CIA) [39,45] was studied. Each mouse
limb was scored for arthritis using a scale of 0 (normal)
to 3 (joint distortion and/or rigidity and swelling) as
described [39]. Real-time qPCR indicated that CD148
mRNA (ptprj) expression was elevated approximately
five-fold in tissue from joints of mice that had severe
arthritis (score 3) compared with mice with a score of 0
(Figure 1).
To determine whether there was any correlation
between CD148 expression and disease pathology,
immunohistochemical studies of CD148 in CIA joint tis-
sue were performed. In normal joints (score 0), Mac-2
staining (a marker of inflammatory macrophages) was
sparse in the synovium and was restricted to chondro-
cytes in the cartilage (Figure 2B). As expected, disease
progression and severity was associated with an increase
in immunoreactivity for Mac-2 (Figure 2D, F). In the
normal joint few cells showed immunoreactivity to
CD148 (Figure 2A). Score 1 inflamed joints showed little
elevation in either CD148 or Mac2 staining (Figure 2C,
D), however, score 2 joints displayed elevated levels of
Mac2 and a concordant increase in CD148 staining (Fig-
ure 2E, F), indicating infiltration of inflammatory macro-
phages in the bone marrow of inflamed joints. CD148
expression was markedly elevated in score 3 severely
inflamed joints (Figure 3A-F). Thus both CD148 and
Mac-2 expression gradually increased with disease
progression. There was a subpopulation of Mac-2 posi-
tive cells that were negative for CD148, therefore, not
all infiltrating macrophages expressed CD148. Higher
power imaging demonstrated that in score 3 joints
CD148-positive cells were present in the synovial lining,
inflamed joint space, bone marrow and in areas of tissue
destruction and bone resorption (Figure 3). Compared
to normal joints CD148 expression was highly upregu-
lated in articular cartilage (Figure 3A) and in the bone
marrow (Figure 3C). CD148 was strongly associated
with areas of bone resorption (Figure 3E, F; arrowheads).
Mac-2 staining on corresponding sections was indicative
of the extent of inflammation. Therefore, these results
were in accordance with the quantitative real-time PCR
data showing increased CD148 mRNA expression
(Figure 1) confirming that CD148 protein expression
was elevated in CIA joint tissues, and identifying a sub-
population of macrophages that expressed CD148.
Figure 1 CD148 mRNA in mouse collagen-induced arthritis model. RNA was extracted from whole rear paws from the CIA mouse model,
reverse transcribed and used to assess the expression of CD148 by quantitative real-time PCR. CIA score 0 refers to normal joints and 3 to
severely inflamed joints marked by rigidity or joint distortion. The axis shows the relative expression of ptprj (CD148) compared to hprt, a control
housekeeping gene. Data points (+/- SD) represent the average of triplicate samples each from triplicate independent experimental tissues, n =
3. CIA, collagen-induced arthritis; PCR, polymerase chain reaction.
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Immunofluorescent localization of CD148 in two murine
models of arthritis
To further investigate the inflammatory cells expressing
CD148, two-colour immunofluorescence was performed
on joint tissue from both the CIA and the KRN models of
experimental arthritis. Collagen-induced arthritis develops
in some of the joints of mice after immunisation and
boosting with collagen (CIA model). The KRN model uti-
lises mice expressing the transgenic T cell receptor (TCR)
KRN plus the MHC class II Ag7 (K/BxN mice). The advan-
tage of this model is that the animals uniformly develop
severe inflammatory arthritis, and serum from these mice
reliably causes arthritis in many recipient strains. Develop-
ment of disease requires the presence of T and B cells and
autoantibodies to glucose-6-isomerase develop [43,44].
Tissue sections were stained for CD148 and either F4/80
(macrophage lineage) or CD3 (T cells). There was elevated
staining of CD148 in both models of the disease (Figure
4). There was only limited co-staining of CD148 with CD3
in both the CIA and KRN mice (Figure 4B, C). However
there was substantial co-staining of CD148 with F4/80 on
both models (Figure 4E, F). Thus the majority of cells
expressing CD148 in arthritic joints in mice in both
inflammatory models were macrophages.
CD148 is present in infiltrating cells in human arthritis
joints
To determine whether CD148 was present in synovial
joints in human rheumatoid arthritis patients, immuno-
fluorescence was performed with CD148 and CD68 (as a
marker for macrophages); CD11c (as a marker for dendri-
tic cells); CD3 (as a marker for T cells and/or thymocytes);
Figure 2 Immunohistochemical detection of CD148 in joints from mice with differing collagen-induced arthritis severities .
Immunohistochemical staining for CD148 (A, C, E) and Mac-2 (B, D, F) protein expression (brown) was performed on joint tissue sections from
CIA-immunized mice with score 0 (A, B), score 1 (C, D) and score 2 (E, F). All sections were counterstained with haematoxylin. AC, articular
cartilage; BM, bone marrow; CIA, collagen-induced arthritis; J, joint space. Arrowhead denotes synovium. Magnification: x200; bar = 100 μm.
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CD90 (as a marker for stromal fibroblasts and endothe-
lium); and von Willebrand factor (vWF) (as a marker for
endothelial cells/blood vessels). CD148 was readily
detectable in rheumatoid joints (Figure 5A). Four-colour
immunofluorescence was used to determine which
cells expressed CD148. A proportion of cells showed
Figure 3 Immunohistochemical staining of score 3 collagen-induced arthritis joints for CD148. Anti-CD148 (A, C, E) and Mac2 staining (B,
D, F) in score 3 joints. AC, articular cartilage; BM, bone marrow; G, isotype control nonimune IgG staining of score 3 joint; J, joint space.
Arrowhead depicts area of bone resorption. Magnification: x200 (A-D); x400 (E-G); scale bar = 100 μm.
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co-expression of CD11c and CD148, although the majority
of cells were single positive for these proteins (Figure 5C).
There was a subpopulation of cells that were double posi-
tive for CD148 and CD68 (Figure 5E), and a considerable
number of cells were double positive for CD148 and CD3,
although there were a number of CD148-positive/CD3-
negative cells (Figure 5B). Endothelial cells, as identified by
vWf, showed only low level staining for CD148 (Figure 5D,
G). CD90-positive mesenchymal/stromal cells were gener-
ally negative for CD148 (Figure 5F, G). Taken together, we
conclude that CD148 is preferentially expressed on T cells,
macrophages and dendritic cells infiltrating the synovium
(Figure 5, B, C, E).
CD148 is differentially expressed in synovial and blood T
cells and monocytes in rheumatoid arthritis patients
To quantify the expression of CD148 in different leukocyte
subpopulations, flow cytometry was performed on periph-
eral blood cells from control and RA patients and from
synovial fluid cells of RA patients. There was increased
expression of CD148 in both CD4+ and CD8+ T cells in
the peripheral blood of RA patients compared to controls
(Figure 6B). When comparing T cells from the same
patients, synovial fluid-derived CD4+ and CD8+ T cells
had elevated levels of CD148 compared to the correspond-
ing peripheral blood T cells (Figure 6B). Further analysis
of CD4/CD45RO or CD8/RO double-positive cells showed
a statistically significant increase in CD148 expression in
synovial fluid-derived T cells compared with peripheral
blood T cells, and a significant increase in CD148 expres-
sion in peripheral blood T cells from RA patients
compared to peripheral blood T cells from control
patients (Figure 6C). In contrast to this, there was a statis-
tically significant decrease in CD148 expression in synovial
fluid-derived CD14+ macrophages compared with periph-
eral blood-derived CD14+ macrophages from RA patients,
whilst there was no significant difference in CD148
expression in peripheral blood macrophages from control
or RA patients (Figure 6D). There was no significant dif-
ference in CD148 expression in peripheral blood-derived
neutrophils or synovial fluid neutrophils from RA patients
(Figure 6A).
Synovial fluid from rheumatoid arthritis patients
suppresses CD148 activity
Since CD148 was upregulated in CD4-positive T cells
from rheumatoid joints, we asked whether the rheuma-
toid synovial environment might regulate CD148 func-
tion. CD4+ peripheral blood T cells were isolated from
normal volunteers and activated using anti-CD3 and
gamma-irradiated EBV B cells. Cells were then treated
with fresh medium containing SF from RA patients, or
TNF. Alternatively cells were exposed to hydrogen per-
oxide for 60 min prior to lysis. CD148 was captured on
Figure 4 Expression of CD148 is upregulated in two mouse models of arthritis. Expression of CD148 is associated with T cells and
macrophages. Two-colour immunofluorescence of CD148 with T cell marker CD3 (A-C) or macrophage marker F4/80 (D-F) in control unaffected
animals, KRN arthritic and CIA arthritic mouse joints. CD3 or F4/80 (red), CD148 (blue), nuclei (grey). Co-expression appears as magenta. For each
set of colours an example of a control, KRN and CIA joint is shown. The bone-synovial interface is marked with a white line for clarity. The
images in this figure are representative of two experiments. All images are at the same magnification, scale bar is 50 μm. CIA, collagen-induced
arthritis.
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96-well plates coated with anti-CD148 and phosphatase
activity measured [46]. SF significantly reduced the phos-
phatase activity of CD148 in a dose-dependent manner
(Figure 7A). Short-term exposure to hydrogen peroxide
also substantially reduced CD148 activity (Figure 7B). In
contrast, 0.1 ng/ml TNF significantly elevated CD148
phosphatase activity (Figure 7C).
Discussion
CD148 has been proposed to be a tumour suppressor in
epithelial cells [47,48]. However, we show here that
CD148 mRNA is highly expressed in macrophages and
we further show that CD148 protein is upregulated in
both experimental arthritis in mice and in human rheu-
matoid arthritis joints.
In murine arthritis qRT-PCR indicated increased levels
of total CD148 mRNA in inflamed joints. Immunohisto-
chemical studies revealed that the elevation in CD148
expression was strongly associated with Mac-2-positive
inflammatory macrophages, suggesting a correlation
between the extent of inflammation and CD148 expres-
sion. Activation of macrophages by TLR agonists
induces expression of CD148 [29]. Since TLR engage-
ment leads to nuclear factor kappa-light-chain-enhancer
of activated B cells (NFkB) activation and is associated
with an M1 phenotype, and CSF-1 (which downregu-
lates CD148) is associated with an M2 phenotype, it
appears that CD148 upregulation may correlate with an
M1 phenotype. This is consistent with the presence of
M1 mediators such as TNFa and IL1b in inflamed
Figure 5 Multi-colour immunofluorescence of CD148, CD68, CD11c, CD3, CD90 and von Willebrand factor in human rheumatoid
arthritis joints. Frozen sections of human RA joints were stained as described in Materials and methods. Four-colour immunofluorescence was
performed with CD148 plus CD3/CD11c/vWF (panels A-D) or CD148 plus CD68/CD90/vWF (panels E-G). Panel H is a control with no primary
antibody. RA, rheumatoid arthritis; vWF, von Willebrand factor.
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synovium. Immunofluorescence of human rheumatoid
arthritis tissue also showed expression of CD148 in
inflammatory joints, however in this case, CD148
expression was found mainly in infiltrating T cells with
some expression in inflammatory macrophages. Quanti-
fication revealed that CD148 expression was increased
in peripheral blood T cells from RA patients compared
to control patients. Furthermore, in RA patients, syno-
vial fluid-derived T cells had increased levels of CD148
compared to circulating T cells, again confirming that
CD148 is differentially expressed in infiltrating inflam-
matory cells in RA joints. In contrast there were no dif-
ferences in CD148 levels in circulating monocytes from
RA patents compared with controls, and in fact there
was a decrease in CD148 levels in synovial fluid-derived
monocytes compared with circulating monocytes from
RA patients. Our results are consistent with previous
reports that mouse naïve T cells express little or no
Figure 6 Flow cytometry of CD148 in peripheral blood and synovial fluid cells of rheumatoid arthritis patients. Cells were isolated either
from peripheral blood or synovial fluid from RA patients or control patients as described in Materials and methods and subjected to flow
cytometric analysis for CD148 and immune cell markers. (A) Flow cytometry of CD148 in PMNs from blood or synovial fluid of RA patient. (B)
Flow cytometry of CD148 expression in CD8-positive or CD4-positive T cells (upper panels) from normal, RA patient blood or synovial fluid. (C)
Quantitation of CD148 in CD8/CD45RO or CD4/CD45RO double positives. (D) Quantitation of CD148 expression in CD14-positive macrophages.
In panels A, B and D clear areas under the curve are isotype control, grey shaded areas are anti-CD148, and filled black shading shows the
expression of CD148 above isotype control. MFI, mean fluorescence intensity; PMN, polymorphonuclear neutrophils; RA, rheumatoid arthritis; n =
3; error bars depict SEM.
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CD148, whereas human T cells express significant levels.
There is no information on the expression of CD148 in
different subpopulations of T cells or macrophages in
arthritic diseases. The synovial environment plays a role
in regulating cells activity [49,50]. Since immunofluores-
cence of human arthritic joints revealed that CD148 was
primarily in T cells with lower apparent expression in
macrophages, and quantification showed increased levels
in T cells and lower levels of CD148 in macrophages
from arthritic joints, we investigated whether the activity
of CD148 in T cells might be modified by an inflamma-
tory or SF environment. We found that SF from RA
Figure 7 Modulation of CD148 phosphatase activity in CD4+ T cells by synovial fluid, hydrogen peroxide and tumour necrosis factor.
Human CD4+ T cells were isolated and activated using anti-CD3 and gamma-irradiated EBV B cells. Two days after activation cells were treated
with the indicated concentrations of synovial fluid (A), hydrogen peroxide (B) or 0.1 ng/ml TNFa (C) as described in Materials and methods.
CD148-associated tyrosine phosphatase activity was measured by a fluorescence assay as described in Materials and methods. EBV, Epstein-Barr
virus; TNFa, tumour necrosis factor alpha. Bars indicate SEM; n = 8 (for panel A); n = 3 (for panels B and C).
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patients significantly reduced CD148 activity in CD4+ T
cells. SF is an oxidizing environment that also contains
high concentrations of cytokines such as TNF, therefore
we investigated the effects of these agents on CD148
activity. As expected, hydrogen peroxide (as an oxidising
agent) inhibited CD148 activity, presumably by oxidizing
the essential Cys1240 in the catalytic site of the mole-
cule [51]. However, we also found that TNF increased
CD148 activity in CD4+ T cells. Thus, despite an
increase in CD148 in isolated synovial T cells (Figure
6B, C), and high levels of TNF that, in isolation, would
increase CD148 activity, we conclude that SF contains
additional factors that counteract this to result in an
overall inhibitory effect on CD148 activity. It is possible
that SF contains other cytokines that suppress CD148
suppression, or other factors that maintain an oxidising
environment. Since CD148 positively regulates T cell
function we therefore expect that overall suppression of
CD148 PTP activity in rheumatoid joints would sup-
press T cell activation. This may contribute to the
observed lack of responsiveness of synovial T cells
[49,50]. Whilst immunocytochemistry appears to show
macrophage expression of CD148 in tissue joints (Figure
3), macrophages isolated from SF show a reduced
expression of CD148 (Figure 6D). This is additional evi-
dence that SF contains factors that influence CD148
expression in macrophages as well as in T cells as dis-
cussed previously.
CD148 expression is upregulated in other chronic
inflammatory diseases such as Crohn’s disease and
Cogan’s syndrome [52,53]. The possible function of
CD148 in inflammation could be similar to that of
CD45 [54-56] whereby it enhances T cell and BCR
signalling by dephosphorylating the auto-inhibitory
phosphotyrosine residues on SFKs [57,58]. Indeed,
recent studies have revealed that CD45 and CD148 have
overlapping functions and can activate SFKs in
monocytes. CD148 negatively regulates neutrophil
responses to chemokines by preferentially targeting the
lyn tyrosine kinase and regulating G-protein-coupled
receptor (GPCR) signalling [35]. The discrepancies
between reports that CD148 can be a negative regulator
or a positive of cell activation might be explained by the
relative expression levels in cells. Recently, it has been
shown that in endothelial cells, low-level expression of
CD148 leads to promotion of responses by dephosphor-
ylating Y529 of c-src, favouring VEGF-promoted prolif-
eration. However, at higher expression levels, CD148
also dephosphorylates Y418 of c-src, attenuating down-
stream proliferation signals [20]. It is possible that there
may also be differential thresholds for signalling pathway
regulation in either T cells or macrophages. Two recent
publications have proposed ligands for the extracellular
domain of CD148. Thrombospondin-1 binds to the
extracellular domain of CD148 with high affinity, and
this activates its catalytic activity leading to dephosphor-
ylation of substrates [59]. Syndecan 2 has been identified
as another novel ligand for CD148, triggering activation
of the C2b isoform of PI-3 kinase and subsequent b1
integrin-mediated adhesion [60]. It is interesting to note
that both thrombospondin and syndecans are increased
during inflammatory arthritis [61,62]. We have pre-
viously shown that an antibody against CD148 inhibits
monocyte chemotaxis [28], thus there is growing evi-
dence that CD148 can regulate cell motility. Both cell
migration and adhesion are key markers of an inflam-
matory response, therefore differential activation of
CD148 in inflammatory cells and a coordinate increase
in endogenous ligand(s) could lead to an enhancement
of the inflammatory response in migratory cells. The
current results indicate that CD148 is highly regulated
by inflammatory stimuli, however, the precise mechan-
ism involved in the regulation of inflammation by
CD148 remains to be elucidated.
Conclusions
CD148 is a tyrosine phosphatase that has been impli-
cated in cell growth and motility and its activity has
been previously shown to enhance leukocyte activation
by increasing SFK activity. We show here that in murine
models of arthritis CD148 is upregulated in diseased tis-
sue and is expressed at high levels in macrophages. In
human RA CD148 is upregulated in both T cells and
macrophages and in addition TNFa, a cytokine enriched
in RA synovial fluid, can increase the tyrosine phospha-
tase activity of CD148. In contrast, both synovial fluid
and an oxidizing environment reduce CD148-associated
PTP activity. Thus CD148 in arthritic tissue can be
regulated at both gene expression level and biochemical
activity level. This regulation may results in enhanced
cell activation in inflammatory lesions leading to an
enhanced response. Whilst the current results indicate
that CD148 is highly regulated by proinflammatory sti-
muli the precise mechanism underlying this regulation
of inflammation remains to be elucidated.
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